|1.||Asthma (Bronchial Asthma)
|1.||Rothenberg, Marc E: 41 articles (05/2015 - 02/2002)|
|2.||Gelfand, Erwin W: 20 articles (07/2014 - 04/2002)|
|3.||Takeda, Katsuyuki: 18 articles (07/2014 - 07/2002)|
|4.||Tefferi, Ayalew: 17 articles (03/2010 - 05/2002)|
|5.||Cross, Nicholas C P: 16 articles (12/2015 - 08/2002)|
|6.||Dellon, Evan S: 15 articles (11/2015 - 04/2010)|
|7.||Foster, Paul S: 15 articles (09/2015 - 02/2002)|
|8.||Dakhama, Azzeddine: 14 articles (07/2014 - 04/2002)|
|9.||Hamid, Qutayba: 14 articles (09/2012 - 09/2002)|
|10.||Joetham, Anthony: 13 articles (04/2014 - 07/2002)|
|1.||Immunoglobulin E (IgE)IBA
08/01/1994 - "The characteristic clinical and laboratory findings of the disease, which are helpful for obtaining definitive diagnosis, include severe asthmatic attacks, the presence of multiple pulmonary infiltrates, skin lesions, marked peripheral eosinophilia, elevation of serum IgE. "
03/01/2014 - "The active treatment with pleuran resulted in a significant reduction of peripheral blood eosinophilia and stabilised the levels of total IgE in serum. "
05/01/2003 - "Treatment of Derp mice with rhSP-D led to significant reduction in Derp-specific IgE levels, blood eosinophilia and pulmonary cellular infiltration. "
12/01/2001 - "In addition, rapid improvement in eosinophilia and hyper-IgE-emia was observed. "
07/01/1999 - "We also found a significant reduction in nasal lavage eosinophilia and serum levels of OVA-specific IgE. "
|2.||Prednisolone (Predate)FDA LinkGeneric
03/01/2003 - "After the administration of prednisolone, the patient's general condition, eosinophilia, ECG abnormalities, and histological findings were improved dramatically. "
10/01/2003 - "Administration of prednisolone at 80 mg/day resulted in a marked improvement of the symptoms and the eosinophilia. "
12/01/2011 - "High dose prednisolone induced a clear improvement in symptoms, with decrease of the inflammatory signs and the eosinophilia and a clear improvement of the left ventricular function."
05/01/2000 - "Finally, administration of prednisolone, which has been shown previously to reduce the concentration of CTLs in dystrophic muscle, produced a significant reduction in eosinophilia. "
11/14/1989 - "Prednisolone (100 mg/die initially, decreasing doses thereafter) led to significant reduction of infiltrates and eosinophilia. "
|3.||Adrenal Cortex Hormones (Corticosteroids)IBA
07/01/2009 - "After starting high-dose corticosteroids, the ejection fraction dramatically improved, the eosinophilia decreased and the patient made a full recovery."
12/01/2005 - "Corticosteroids significantly improved clinical symptoms and esophageal histology; however, upon their withdrawal, the symptoms and esophageal eosinophilia recurred. "
02/01/1996 - "Patients with disabling symptoms can be effectively treated with corticosteroids after other systemic disorders associated with peripheral eosinophilia have been excluded. "
06/01/2015 - "These two important new studies suggested that this treatment could reduce exacerbation rates by 50% in asthmatic patients with persistent peripheral blood eosinophilia and persistent symptoms despite high-dose-inhaled corticosteroids and additional controller therapy, and frequent exacerbations. "
01/01/2011 - "At the end of the study, subjects had 1 week of open label treatment with nasal corticosteroids if they had nasal eosinophilia or an antibiotic if they had nasal neutrophilia. "
|4.||imatinib (Gleevec)FDA Link
05/01/2003 - "Here, we present the case of a patient, with MPD/MDS, and eosinophilia, carrying a translocation t(5;12)(q33;p13) who achieved a complete remission following treatment with STI571, 400 mg daily. "
06/01/2009 - "Imatinib in treatment of MPN with eosinophilia and positive FIP1L1-PDGFR alpha gene patients can induce high hematologic and molecular remission. "
01/01/2006 - "Improvement in peripheral eosinophilia after Glivec therapy correlated with improved clinical status."
04/01/2014 - "However, the dramatic response to imatinib emphasizes the need to study the presence of the fusion product FIP1L1/PDGFRA in all patients with eosinophilia of unknown etiology. "
08/01/2006 - "We now extend our observations through a study of 741 unselected patients with eosinophilia for FIP1L1-PDGFRA, and present longer term follow up data for the imatinib-treated cohort. "
12/01/2012 - "The unique features were the prominent involvement of the cerebral cortex and the dramatic response to steroids with marked improvement of eosinophilia and brain function. "
09/01/2011 - "Steroids are effective in relieving symptoms and improving eosinophilia."
04/01/2005 - "The protective effects of inhaled steroids against allergen-induced early responses, airway eosinophilia, and allergen-induced airway hyperresponsiveness are partially or completely lost as early as 12 hours after discontinuation of therapy."
08/01/2015 - "A failure to respond to oral steroids in the context of good compliance suggests a malignant cause for the eosinophilia. "
05/01/2014 - "However, a peripheral blood eosinophilia must not lead to an automatic use of steroids before the most important core tests, as this can compromise further diagnostic measures. "
01/01/2015 - "The results in this study suggest that FG nanoparticle vaccination induces long-term protection against RSV and that AMs play a role in the RSV protection by modulating eosinophilia, mucus production, inflammatory cytokines, and T-cell infiltration. "
01/01/2011 - "Early studies have suggested that esophageal eosinophilia occurs in association with T(H)2 allergic responses, yet the local and systemic expression of relevant cytokines has not been well characterized. "
02/01/2005 - "This study attempted to determine the significance of eosinophilia and eosinophil activation in infant cases of AD by comparing multiple clinical parameters, indexes of eosinophil activation, and levels of serum cytokines. "
12/01/1998 - "Results of nasal biopsy studies indicate that the late-phase allergic response involves T-lymphocyte activation, production of TH2-type cytokines and tissue eosinophilia. "
03/01/1998 - "Recent in vitro-studies have substantially increased our knowledge of eosinophil activation, the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process. "
|7.||Interleukin-5 (Interleukin 5)IBA
05/01/2009 - "There was a significant reduction in lung eosinophilia and IL-5 in high-fat fed mice. "
11/01/2009 - "In vivo, interleukin-5 transgenic mice, which have profound eosinophilia, demonstrated improved clearance of Pseudomonas aeruginosa introduced into the peritoneal cavity. "
10/01/1992 - "Following steroid therapy, pleural fluid disappeared, eosinophilia improved and serum IL-5 concentration became undetectable. "
02/01/2009 - "In the present study, the dependence of PGD(2)-induced eosinophil accumulation in vivo on interleukin-5 (IL-5) blood eosinophilia was investigated. "
03/15/2002 - "However, studies using anti-IL-5 mAbs in human asthmatics have failed to suppress lower airway hyperresponsiveness despite suppression of eosinophilia; therefore, it is critical to examine the role of IL-5 and bone marrow responses in the pathogenesis of allergic airway disease. "
02/01/1999 - "ISS is most effective in inhibiting airway eosinophilia when administered as a single dose 6 days prior to antigen inhalation. "
04/01/1997 - "Treatment with this antibody resulted in a significant reduction of the antigen-induced eosinophilia and concentration of [IL-5]BALF. "
12/01/2000 - "These results indicated that chronic administration is more effective in antigen-induced eosinophilia than a single administration. "
02/15/2000 - "In this study, we found that the antigen-induced airway eosinophilia was diminished in Stat5a-deficient (Stat5a(-/-)) mice and Stat5b-deficient (Stat5b(-/-)) mice. "
03/01/1998 - "Dose-response studies in nonasthmatic allergic subjects indicate that the degree of BAL eosinophilia is related to the dose of antigen  but there is as yet no agreement on how LEAC might be standardized. "
07/01/2013 - "In conclusion, our data establish that allergen-induced EoE pathogenesis is independent of IL-13, whereas IL-13 is required for allergen-induced lung eosinophilia. "
07/01/2013 - "In contrast, lung eosinophilia was significantly reduced in mice deficient in IL-13, both IL-4/IL-13 and STAT6 genes following allergen challenge. "
07/01/2013 - "Similarly, we found that esophageal eosinophilia in IL-4/IL-13 double gene-deficient and STAT6 gene-deficient mice were also not reduced following allergen-induced experimental EoE. "
07/01/2013 - "Herein, we report that intranasal delivery of IL-13 promotes IL-5-dependent esophageal eosinophilia. "
01/01/2013 - "Airway eosinophilia and IL-13 production were augmented by poly IC in Kit+/+ mice but not in KitW/KitW-v mice. "
|10.||Interleukin-12 (IL 12)IBA
09/01/2000 - "Mucosal IL-12 is more effective than systemic IL-12 in augmenting IFN-gamma expression and inhibiting allergic lung eosinophilia in murine lungs."
10/15/2006 - "Inhibition of bronchial eosinophilia corresponded with reduced Th2 cytokine production and was independent of IL-12, as evidenced by a similar down-regulatory effect of anti-CD40 mAb in IL-12 p40-deficient mice. "
03/15/2005 - "Recombinant anti-IL-5 and recombinant IL-12 inhibit blood and sputum eosinophils and allergen-induced eosinophilia without any effect on airway responsiveness, allergen-induced airway responses, or allergen-induced airway hyperresponsiveness. "
06/15/2003 - "Using gene-depleted mice, we show that reduction of eosinophilia and pathogen burden requires IL-12 and/or IFN-gamma. "
02/01/2001 - "gondii which is associated with increased small-intestine pathology, eosinophilia, and reduced plasma IL-12 and IFN-gamma levels."
04/01/2013 - "In 8 patients, esophageal eosinophilia was improved histologically at follow-up after treatment. "
06/01/2002 - "After treatment with anti-nematodal agents, the eosinophilia decreased from 26% to 1% and the patient's symptoms improved. "
05/01/1997 - "After treatment, symptoms, FEV1, blood eosinophilia, and serum ECP improved in the first 24 h. "
10/01/2013 - "The increase in forced expiratory volume in one second (FEV(1)) after treatment was greater in patients with sputum eosinophilia (ΔFEV(1) 0.35 ± 0.12 vs. 0.13 ± 0.04 L, p = 0.046), and FENO was a strong predictor of sputum eosinophilia (area under the receiver operating characteristic curve, 0.89). "
01/01/2012 - "In phase I, prevalence of eosinophilia was determined; in phase II, helminth prevalence and degree of eosinophilia before and after treatment were reported. "
|2.||Drug Therapy (Chemotherapy)
07/01/2008 - "Univariate analysis showed that both eosinophilia and inv(16) were correlated with a higher probability of complete remission, lower resistance to chemotherapy and increased overall survival. "
04/01/2003 - "Clinically, this type of AML often shows eosinophilia and has a high complete remission rate with conventional chemotherapy. "
08/01/2010 - "We report a case of AML with del(16)(q22) which showed a complex karyotype, absence of eosinophilia in bone marrow study and a poor response to chemotherapy."
12/01/2014 - "An interesting feature we wish to highlight is the associated eosinophilia that corresponded to disease activity, exhibiting fluctuations with surgical resection and chemotherapy. "
02/01/2009 - "A tumour relapse indicating the recurrence of the erythrodermia and eosinophilia was confirmed 2 months after completion of the chemotherapy. "
06/01/2001 - "Improvement in symptoms after grass pollen immunotherapy may result, at least in part, from inhibition of IL-5-dependent tissue eosinophilia during the pollen season."
03/01/2000 - "Despite a great amount of uncertainty concerning the role of eosinophils, in our study, blood eosinophilia predicts a poor response to immunotherapy in patients with advanced RCC, thus supporting previous observations from our own group."
09/01/2015 - "Moreover, we show that the reduction of eosinophilia and the recruitment of inflammatory monocytes to the lungs required early triggering of TLR9, IFN-γ and CCR2 by immunotherapy components. "
02/01/2004 - "Short-course immunotherapy with AIC can modify the response of nasal mucosa to allergen challenge by increasing T(H)1 cytokine production and decreasing T(H)2 cytokine production and eosinophilia. "
11/01/2001 - "Specific immunotherapy (IT) reduces mucosal eosinophilia and numbers of metachromatic cells in the epithelium. "
10/01/2000 - "Intranasal administration of anti-IL-5 also reduced BAL eosinophilia, partly via local effects in the airways. "
06/01/2000 - "Intranasal administration of Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) has been demonstrated to suppress airway eosinophilia in a model of atopic asthma. "
08/01/2013 - "Intranasal administration of Gcf induced antibody response and increased IFNγ secretion and protected mice against RSV challenge without severe lung eosinophilia, even in the presence of high levels of RSV-specific maternal antibodies. "
04/01/2003 - "PGD(2) is known to induce eosinophilia following intranasal administration, and to induce eosinophil activation in vitro. "
03/15/1998 - "Intranasal administration of either Ad/TNFalpha or Ad/IL-4 into OVA-sensitized and -challenged CD40L-KO mice did not reconstitute airway eosinophilia. "
12/01/2000 - "A subcutaneous injection of rIL-5 (10 pmol/kg) at the remote site (left ear lobe) 12 h after challenge induced transient blood eosinophilia and enhanced eosinophil accumulation in the challenged ear lobe. "
02/01/1993 - "This study demonstrated that rIFN-gamma given by daily subcutaneous injection over a 12-week period was safe, well accepted, and effective in reducing inflammation, clinical symptoms, and eosinophilia in severe atopic dermatitis."
03/01/1997 - "Subcutaneous injection of eotaxin induced a local tissue eosinophilia in wild type mice but not in IL-5 deficient mice. "
11/01/2011 - "Non-allergic delayed skin reactions from intradermal and, to a minor degree, subdermal and subcutaneous injections of insulin detemir were frequent in this experimental study and showed a consistent histology pattern of inflammation with eosinophilia. "
01/01/1995 - "Despite promoting a prominent tissue eosinophilia, the repetitive subcutaneous injections of rHu IL-5 did not alter the clearance of FITC-dextran 150. "